1-adamantyl propargyl ether | 119728-80-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-adamantyl propargyl ether
• 英文别名: 1-Prop-2-ynyloxy-adamantane；1-prop-2-ynoxyadamantane
• CAS: 119728-80-2
• 化学式: C₁₃H₁₈O
• 分子量: 190.285
• InChiKey: PAPVRHXVKGGCHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-adamantyl propargyl ether 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 生成 (1r,3r,5r,7r)-2-(propa-1,2-dien-1-yloxy)adamantine
  参考文献：
  名称：

  Asymmetric Pd/Organoboron‐Catalyzed Site‐Selective Carbohydrate Functionalization with Alkoxyallenes Involving Noncovalent Stereocontrol

  摘要：

  Herein, we demonstrate the robustness of a synergistic chiral Pd/organoboron system in tackling a challenging suite of site‐, regio‐, enantio‐ and diastereoselectivity issues across a considerable palette of biologically relevant carbohydrate polyols, when prochiral alkoxyallenes were employed as electrophiles. In view of the burgeoning role of noncovalent interactions (NCIs) in stereoselective carbohydrate synthesis, our mechanistic experiments and DFT modeling of the reaction path unexpectedly revealed that NCIs such as hydrogen bonding and CH‐π interactions between the resting states of the Pd‐π‐allyl complex and the borinate saccharide are critically involved in the stereoselectivity control. Our strategy thus illuminates the untapped potential of harnessing NCIs in the context of transition metal catalysis to tackle stereoselectivity challenges in carbohydrate functionalization.

  DOI：

  10.1002/anie.202400912
• 作为产物：
  描述：

  1-Prop-1-ynyloxy-adamantane 在 potassium salt of 1,3-diaminopropane 作用下， 以 正己烷 为溶剂， 反应 4.0h， 以70%的产率得到1-adamantyl propargyl ether
  参考文献：
  名称：

  A Convenient Procedure for the Synthesis of Propargyl Ethers Derived from Secondary Alcohols

  摘要：

  描述了一种新颖且高效的两步合成二级醇衍生的丙炔醚的方法，该方法涉及形成1-丙炔基醚，随后与氨基丙胺钾进行异构化。该过程对起始醇的立体位阻不敏感。

  DOI：

  10.1055/s-1988-27680

文献信息

• Gastrin and cholecystokinin receptor lignads (iv)
  申请人：——

  公开号：US20030195237A1

  公开（公告）日：2003-10-16

  1 Compounds of the formula (I) or (II) and their pharmaceutically acceptable salts are ligands at gastrin and/or chole-cystokinin receptors. n is from 1 to 4; R 4 is C 1 to C 15 hydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; Z is —(NR 5 ) a —CO—(NR 6 ) b -(wherein a is 0 or 1, b is 0 or 1, and R 5 and R 6 are independently selected from H, Me, Et, Pr, Bn), —CO—NR 5 —CH 2 —CO—NR 6 —, —CO—O—, —CH 2 —CH 2 —, —CH═CH—, CH 2 —NR 6 — or a bond; Q is R 7 V, or(a) wherein R 7 is —CH 2 —; —CH 2 —; or(b) R 7 and R 6 , together with the nitrogen atom to which R 6 is attached, form a piperidine or pyrrolidine ring which is substituted by V; V is —CO—NH—SO 2 —Ph, —SO 2 —NH—CO—Ph, CH 2 OH, or a group of the formula —R 8 U, (wherein U is —COOH, tetrazolyl, —CONHOH— or —SO 3 H; and R 8 is a bond; C 1 to C 6 hydrocarbylene, optionally substituted by hydroxy, amino or acetamino; —O-(C 1 to C 3 alkylene)-; —SO 2 NR 9 —CHR 10 —; —CO—NR 9 CHR 10 —, R 9 and R 10 being independently selected from H and methyl; or —NH—(CO) c —CH 2 —, c being 0 or 1); m is 1 or 2; q is from 0 to 2, with the proviso that q is 1 or 2 when Z is a bond); Compositions comprising a compound of formula (I) or (II) are also described.

  化合物(I)或(II)的配方及其药学上可接受的盐是胃泌素和/或胆囊肽受体的配体。其中n为1至4; R4为C1至C15烃基，其中最多可有两个C原子被N、O和/或S原子替换，最多可有三个H原子被卤素原子替换; Z为-(NR5)a-CO-(NR6)b-(其中a为0或1，b为0或1，R5和R6独立选择自H、Me、Et、Pr、Bn)、-CO-NR5-CH2-CO-NR6-、-CO-O-、-CH2-CH2-、-CH=CH-、CH2-NR6-或键; Q为R7V或(a)其中R7为-CH2-; -CH2-; 或(b) R7和R6与R6所连接的氮原子一起形成一个被V取代的哌啶或吡咯烷环; V为-CO-NH-SO2-Ph、-SO2-NH-CO-Ph、CH2OH或一个公式为-R8U的基团(其中U为-COOH、四唑基、-CONHOH-或-SO3H; R8为键; C1至C6烃基亚亚甲基，可选择地被羟基、氨基或乙酰氨基取代; -O-(C1至C3烷基)-; -SO2NR9-CHR10-; -CO-NR9CHR10-，其中R9和R10独立选择自H和甲基; 或-NH-(CO)c-CH2-，其中c为0或1); m为1或2; q为0至2，但当Z为键时，q为1或2。还描述了包含化合物(I)或(II)的组成物。
• FMO3 inhibitors for treating pain
  申请人：Akron Molecules GmbH

  公开号：EP2674161A1

  公开（公告）日：2013-12-18

  The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.

  本发明涉及治疗疼痛和相关疾病的新疗法，以及用于上述疗法的药物化合物。
• Electrolyte additives containing one, two, or more triple-bonded moieties for silicon anode-based li-ion batteries
  申请人：Enevate Corporation

  公开号：US11539077B2

  公开（公告）日：2022-12-27

  Electrolyte additives for energy storage devices comprising compounds containing one, two, or more triple-bonded moieties are disclosed. The energy storage device comprises a first electrode and a second electrode, wherein at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, and an electrolyte composition. Compounds containing one, two, or more triple-bonded moieties may serve as additives to the electrolyte composition.

  本发明公开了用于储能装置的电解质添加剂，该添加剂包含含有一个、两个或多个三键分子的化合物。储能装置包括第一电极和第二电极（其中第一电极和第二电极中至少有一个是硅基电极）、第一电极和第二电极之间的隔板以及电解质组合物。含有一个、两个或多个三键分子的化合物可作为电解质组合物的添加剂。
• Strobel, Sharon M.; Szklarz, Grazyna D.; He, You Qun, Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 290, # 1, p. 445 - 451
  作者：Strobel, Sharon M.、Szklarz, Grazyna D.、He, You Qun、Foroozesh, Maryam、Alworth, William L.、Roberts, Elizabeth S.、Hollenberg, Paul F.、Halpert, James R.

  DOI：——

  日期：——
• COMPOUNDS AND METHODS FOR TREATING PAIN
  申请人：Akron Molecules GmbH

  公开号：EP2637649A2

  公开（公告）日：2013-09-18